A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.
Richard D KimHanna K SanoffAndrew S PoklepovicHeloisa SoaresJongphil KimJing LyuYingmiao LiuAndrew B NixonDae Won KimPublished in: Cancer (2020)
Regorafenib demonstrated modest clinical efficacy in heavily pretreated patients with BTC. Further exploration of biomarkers is warranted to identify a group of patients with BTC who may benefit from regorafenib.